Genistein is a phytoestrogen and belongs to the category of isoflavones. Genistein was first isolated in 1899 from the dyer's broom, Genista tinctoria; hence, the chemical name derived from the generic name. The compound nucleus was established in 1926, when it was found to be identical with prunetol. It was chemically synthesized in 1928.
Most of the isoflavones in plants are present in a glycosylated form. The unglycosylated aglycones can be obtained through various means such as treatment with the enzyme β-glucosidase, acid treatment of soybeans followed by solvent extraction, or by chemical synthesia. Acid treatment is a harsh method as concentrated inorganic acids are used. Both enzyme treatment and chemical synthesis are costly. A more economical process consisting of fermentation for in situ production of β-glucosidase to isolate genistein has been recently investigated.
Isoflavones genistein and daidzein bind to and transactivate all three PPAR isoforms, α, δ, and γ. For example, membrane-bound PPARγ-binding assay showed that genistein can directly interact with the PPARγ ligand binding domain and has a measurable Ki of 5.7 mM. Gene reporter assays showed that genistein at concentrations between 1 and 100 uM activated PPARs in a dose dependent way in KS483 mesenchymal progenitor cells, breast cancer MCF-7 cells, T47D cells and MDA-MD-231 cells, murine macrophage-like RAW 264.7 cells, endothelial cells and in Hela cells. Several studies have shown that both ERs and PPARs influenced each other and therefore induce differential effects in a dose-dependent way. The final biological effects of genistein are determined by the balance among these pleiotrophic actions.
Due to its structure similarity to 17β-estradiol (estrogen), genistein can compete with it and bind to estrogen receptors. However, genistein shows much higher affinity toward estrogen receptor β than toward estrogen receptor α.
Data from in vitro and in vivo research confirms that genistein can increase rate of growth of some ER expressing breast cancers. Genistein was found to increase the rate of proliferation of estrogen-dependent breast cancer when not cotreated with an estrogen antagonist. It was also found to decrease efficiency of tamoxifen and letrozole - drugs commonly used in breast cancer therapy. Genistein was found to inhibit immune response towards cancer cells allowing their survival.
Isoflavones can act like estrogen, stimulating development and maintenance of female characteristics, or they can block cells from using cousins of estrogen. In vitro studies have shown genistein to induce apoptosis of testicular cells at certain levels, thus raising concerns about effects it could have on male fertility; however, a recent study found that isoflavones had "no observable effect on endocrine measurements, testicular volume or semen parameters over the study period." in healthy males given isoflavone supplements daily over a 2-month period.
Genistein was, among other flavonoids, found to be a strong topoisomerase inhibitor, similarly to some chemotherapeutic anticancer drugs ex. etoposide and doxorubicin. In high doses it was found to be strongly toxic to normal cells. This effect may be responsible for both anticarcinogenic and carcinogenic potential of the substance. It was found to deteriorate DNA of cultured blood stem cells, what may lead to leukemia. Genistein among other flavonoids is suspected to increase risk of infant leukemia.
Genistein decreases pathological accumulation of glycosaminoglycans in Sanfilippo syndrome. In vitro animal studies and clinical experiments suggest that the symptoms of the disease may be alleviated by adequate dose of genistein. Genistein was found to also possess toxic properties toward brain cells. Among many pathways stimulated by genistein, autophagy may explain the observed efficiency of the substance as autophagy is significantly impaired in the disease.
^Kaufman PB, Duke JA, Brielmann H, Boik J, Hoyt JE (1997). "A comparative survey of leguminous plants as sources of the isoflavones, genistein and daidzein: implications for human nutrition and health.". J Altern Complement Med3 (1): 7–12. doi:10.1089/acm.1997.3.7. PMID9395689.
^Prakash O, Tanwar MP (1995). "Hypervalent iodine oxidation of favanones: Convenient and useful syntheses of favones and isofavones". J Chem Res.26: 1429–1447.
^Pandit, N. T., & Patravale, V. B. (2011). "Design and optimization of a novel method for extraction of genistein". Indian journal of pharmaceutical sciences73 (2): 184.
^Gossner, G.; Choi, M.; Tan, L.; Fogoros, S.; Griffith, KA.; Kuenker, M.; Liu, JR. (Apr 2007). "Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells". Gynecol Oncol105 (1): 23–30. doi:10.1016/j.ygyno.2006.11.009. PMID17234261.
^ abNakamura, Y.; Yogosawa, S.; Izutani, Y.; Watanabe, H.; Otsuji, E.; Sakai, T. (2009). "A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy". Mol Cancer8: 100. doi:10.1186/1476-4598-8-100. PMC2784428. PMID19909554.
^Dang, Z.C. Audinot V.; Papapoulos, S. Boutin J.A.; Löwik, C.; Boutin, JA; Löwik, CW (2003). "Peroxisome proliferator-activated receptor g (PPARg) as a molecular target for the soy phytoestrogen genistein". Journal of Biological Chemistry278 (2): 962–967. doi:10.1074/jbc.M209483200. PMID12421816.
^Dang, Z.C.; Löwik, C. (2005). "Dose-dependent effects of phytoestrogens on bone: molecular mechanisms, review paper". Trends in Endocrinology and Metabolism16 (5): 207–213. doi:10.1016/j.tem.2005.05.001. PMID15922618.
^Markovits, J.; Linassier, C.; Fossé, P.; Couprie, J.; Pierre, J.; Jacquemin-Sablon, A.; Saucier, JM.; Le Pecq, JB. et al. (Sep 1989). "Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II". Cancer Res49 (18): 5111–7. PMID2548712.|displayauthors= suggested (help)
^López-Lazaro, M.; Willmore, E.; Austin, CA. (May 2007). "Cells lacking DNA topoisomerase II beta are resistant to genistein". J Nat Prod70 (5): 763–7. doi:10.1021/np060609z. PMID17411092.
^Mann, GE.; Bonacasa, B.; Ishii, T.; Siow, RC. (Apr 2009). "Targeting the redox sensitive Nrf2-Keap1 defense pathway in cardiovascular disease: protection afforded by dietary isoflavones". Current Opinion in Pharmacology9 (2): 139–45. doi:10.1016/j.coph.2008.12.012. PMID19157984.
^ abTandon V, Pal P, Roy B, Rao HS, Reddy KS. (1997). "In vitro anthelmintic activity of root-tuber extract of Flemingia vestita, an indigenous plant in Shillong, India". Parasitol Res83 (5): 492–298. doi:10.1007/s004360050286. PMID9197399.
^Kar PK, Tandon V, Saha N. (2002). "Anthelmintic efficacy of Flemingia vestita: genistein-induced effect on the activity of nitric oxide synthase and nitric oxide in the trematode parasite, Fasciolopsis buski". Parasitol Int51 (1): 249–257. doi:10.1016/S1383-5769(02)00032-6. PMID12243779.
^Tandon V, Das B, Saha N. (2003). "Anthelmintic efficacy of Flemingia vestita (Fabaceae): Effect of genistein on glycogen metabolism in the cestode, Raillietina echinobothrida". Parasitol Int52 (2): 179–183. doi:10.1016/S1383-5769(03)00006-0. PMID12798931.
^Das B, Tandon V, Saha N. (2004). "Anthelmintic efficacy of Flemingia vestita (Fabaceae): alteration in the activities of some glycolytic enzymes in the cestode, Raillietina echinobothrida". Parasitol Res93 (4): 253–261. doi:10.1007/s00436-004-1122-8. PMID15138892.
^Das B, Tandon V, Saha N. (2006). "Effect of isoflavone from Flemingia vestita (Fabaceae) on the Ca2+ homeostasis in Raillietina echinobothrida, the cestode of domestic fowl". Parasitol Int55 (1): 17–21. doi:10.1016/j.parint.2005.08.002. PMID16198617.
^Das B, Tandon V, Lyndem LM, Gray AI, Ferro VA. (2009). "Phytochemicals from Flemingia vestita (Fabaceae) and Stephania glabra (Menispermeaceae) alter cGMP concentration in the cestode Raillietina echinobothrida". Comp Biochem Physiol C Toxicol Pharmacol149 (3): 397–403. doi:10.1016/j.cbpc.2008.09.012. PMID18854226.
^Hwang YW, Kim SY, Jee SH, Kim YN, Nam CM (2009). "Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies". Nutr Cancer61 (5): 598–606. doi:10.1080/01635580902825639. PMID19838933.
^Kim SH, Kim SH, Kim YB, Jeon YT, Lee SC, Song YS (2009). "Genistein inhibits cell growth by modulating various mitogen-activated protein kinases and AKT in cervical cancer cells". Annals of the New York Academy of Sciences1171: 495–500. doi:10.1111/j.1749-6632.2009.04899.x. PMID19723095.
^Arabina DAS, Naren L. BANIK, and Swapan K. RAY (2009). "Flavonoids Activated Caspases for Apoptosis in Human Glioblastoma T98G and U87MG Cells But Not in Human Normal Astrocytes". Cancer116 (1): 164–76. doi:10.1002/cncr.24699. PMC3159962. PMID19894226.
^Sakamoto T, Horiguchi H, Oguma E, Kayama F (2009). "Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells". J Nutr Biochem21 (9): 856–64. doi:10.1016/j.jnutbio.2009.06.010. PMID19800779.
^de Lemos ML (2001). "Effects of soy phytoestrogens genistein and daidzein on breast cancer growth". Annals of Pharmacotherapy35 (9): 1118–21. doi:10.1345/aph.10257. PMID11573864.
^ abDe Assis S, Hilakivi-Clarke L (November 2006). "Timing of dietary estrogenic exposures and breast cancer risk". Annals of the New York Academy of Sciences1089: 14–35. doi:10.1196/annals.1386.039. PMID17261753. "The viability was decreased by co-treatment with genistein and irradiation compared with irradiation treatment alone."
^Markovits J, Linassier C, Fossé P, Couprie J, Pierre J, Jacquemin-Sablon A, Saucier JM, Le Pecq JB, Larsen AK (1989). "Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II". Cancer Res.49 (18): 5111–7. PMID2548712.
^López-Lazaro M, Willmore E, Austin CA. (2007). "Cells lacking DNA topoisomerase II beta are resistant to genistein". J Nat Prod.70 (5): 763–7. doi:10.1021/np060609z. PMID17411092.
^Raynal NJ, Charbonneau M, Momparler LF, Momparler RL (2008). "Synergistic effect of 5-Aza-2'-deoxycytidine and genistein in combination against leukemia". Oncol Res17 (5): 223–30. doi:10.3727/096504008786111356. PMID18980019.
^Ju YH, Allred KF, Allred CD, Helferich WG (June 2006). "Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations". Carcinogenesis27 (6): 1292–9. doi:10.1093/carcin/bgi370. PMID16537557. "Results from this study suggest that consumption of products containing GEN may not be safe for postmenopausal women with estrogen-dependent breast cancer."
^Tonetti, DA.; Zhang, Y.; Zhao, H.; Lim, SB.; Constantinou, AI. (2007). "The effect of the phytoestrogens genistein, daidzein, and equol on the growth of tamoxifen-resistant T47D/PKC alpha". Nutr Cancer58 (2): 222–9. doi:10.1080/01635580701328545. PMID17640169.
^Jiang, X.; Patterson, NM.; Ling, Y.; Xie, J.; Helferich, WG.; Shapiro, DJ. (Nov 2008). "Low Concentrations of the Soy Phytoestrogen Genistein Induce Proteinase Inhibitor 9 and Block Killing of Breast Cancer Cells by Immune Cells". Endocrinology149 (11): 5366–73. doi:10.1210/en.2008-0857. PMC2584580. PMID18669594.
^Kumi-Diaka J, Rodriguez R, Goudaze G (1998). "Influence of genistein (4',5,7-trihydroxyisoflavone) on the growth and proliferation of testicular cell lines". Biol. Cell90 (4): 349–54. doi:10.1016/S0248-4900(98)80015-4. PMID9800352. "Genistein-induced apoptosis identifies genistein as a potential diagnostic and therapeutic tool in testicular pathophysiological research."
^Mitchell JH, Cawood E, Kinniburgh D, Provan A, Collins AR, Irvine DS (2001). "Effect of a phytoestrogen food supplement on reproductive health in normal males". Clin Sci (Lond)100 (6): 613–8. doi:10.1042/CS20000212. PMID11352776.
^Spector LG, Xie Y, Robison LL, Heerema NA, Hilden JM, Lange B et al. (2005). "Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children's oncology group". Cancer Epidemiol Biomarkers Prev14 (3): 651–5. doi:10.1158/1055-9965.EPI-04-0602. PMID15767345.
^Piotrowska, E.; Jakóbkiewicz-Banecka, J.; Barańska, S.; Tylki-Szymańska, A.; Czartoryska, B.; Wegrzyn, A.; Wegrzyn, G. (Jul 2006). "Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses". European Journal of Human Genetics14 (7): 846–52. doi:10.1038/sj.ejhg.5201623. PMID16670689.
^Ballabio, A. (2009). "Disease pathogenesis explained by basic science: lysosomal storage diseases as autophagocytic disorders". Int J Clin Pharmacol Ther. 47 Suppl 1: S34–8. PMID20040309.
^Settembre, C.; Fraldi, A.; Jahreiss, L.; Spampanato, C.; Venturi, C.; Medina, D.; de Pablo, R.; Tacchetti, C. et al. (Jan 2008). "A block of autophagy in lysosomal storage disorders". Hum Mol Genet17 (1): 119–29. doi:10.1093/hmg/ddm289. PMID17913701.|displayauthors= suggested (help)